Janice Dean from Fox News Radio sits down with Founder and Chairman of Survivors for Solutions John Czwartacki to discuss his battle with Multiple Sclerosis and the work he does to protect medical innovations that give people hope across the nation.

It’s time for everyone’s resolutions, personal and professional. At Survivors For Solutions, the new year means bringing about a new kind of advocacy by patients for patients…

It has been about four months since President Biden signed the Inflation Reduction Act (IRA) and, already, the law’s drug-pricing rules have dealt a major blow to medical innovation…

John Czwartacki’s resume is a laundry list of posts throughout pretty much every GOP political arena imaginable — he worked for former House Speaker John Boehner early in his career, as a spokesperson for former Senate Majority Leader Trent Lott, for FEMA in the Bush administration shortly after the 9/11 attacks, and for then-OMB Director Mick Mulvaney in the Trump White House — and now, he’s adding advocacy on drug pricing to his list…

Thirty years ago, as a congressional staffer, I never thought I would be diagnosed with a life-altering disease. I had every reason to be hopeful about my future. I was young, healthy, and solidly independent. Or so I thought…

WASHINGTON – Today, a new patient advocacy group led by multiple sclerosis survivor launched to promote and protect patients’ access to innovative treatments and therapies.

Remember John "Cz" Czwartacki? Worked on the Hill for big names like John Boehner, Bill Paxon and Trent Lott and then in the Trump administration under Mick Mulvaney? He also has MS, and he's launching a patient advocacy group.

It may take years before we can fully appreciate the impact of the Inflation Reduction Act on the pharmaceutical industry..

In a strange political twist, a Republican governor is suing a Democratic administration...for not imposing price controls…

President Biden this week gave a speech promoting his Cancer Moonshot initiative and a new government health agency that he says will drive treatment breakthroughs. As usual, he gave no credit to drug makers that are producing game-changing treatments..